Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors.
The Series B includes $20 million in new equity capital and $5 million in previously issued convertible notes that converted as part of the financing. The new capital will support expanded distribution of Luminoah Flow™, the company’s FDA-cleared enteral feeding system, increased manufacturing capacity, and continued development of Luminoah Intelligence™, its clinician-facing data platform.
Following FDA clearance in April 2026, Luminoah completed an early access program with patients served by leading healthcare institutions in the Pacific Northwest and Southeast.
Reimagining Tube Feeding
For people who depend on tube feeding for essential nutrition, the technology supporting their daily lives has changed little in decades. Traditional feeding pumps often require patients to carry equipment on poles, limiting mobility and independence. Caregivers manage much of the therapy with handwritten feeding logs, while clinicians have limited visibility into how much nutrition patients actually receive.
Neal Piper founded Luminoah after his son, Noah, depended on tube feeding during cancer treatment.
“For too long, families who depend on tube feeding have had to organize their lives around the pump. We built Luminoah so the technology could fit around their lives instead,” said Piper, Founder and Chief Executive Officer of Luminoah. “Our family’s experience inspired a mission to make tube feeding simpler and give people greater freedom. With patients now using our technology and the support of exceptional investors, we’re ready to bring that vision to many more families.”
“We’re thrilled to partner with Neal and the Luminoah team to transform enteral feeding,” said Scott Davis, Venture Partner at GV. “Inspired by his family’s experience, Neal and the team have developed a patient-first solution that supports more active lives, simplifies feeding, and enables remote tracking for better care. We’re excited to support their next chapter.”
Bringing Mobility and Connectivity to Enteral Nutrition
Luminoah Flow combines a pocket-sized, rechargeable feeding pump, nutrition pouches, and a connected mobile app into one system. Patients can receive nutrition while moving through their day and track their feeding activity as the data uploads to the Luminoah mobile app. When patients choose to share their data, clinicians can review delivered nutrition through the Luminoah Intelligence data platform.
“Luminoah is poised to disrupt an outdated and burdensome standard of care in enteral nutrition. By combining compact pump design, a user-friendly interface, and real-time tracking, Luminoah Flow not only improves the patient experience but also directly combats the drivers of poor nutrition plan adherence, which can help prevent hospital readmissions, reduce costs, and free up valuable clinician time,” said Tom Hawes, Managing Director at the Blue Venture Fund and Sandbox Clinical Ventures.
“Enteral nutrition has gone far too long without meaningful innovation. Luminoah is making nutrition therapy more portable, connected, and patient-centered while giving clinicians better information to guide care. That combination of clinical need, patient impact, and thoughtful innovation is exactly what we look for through the AGA GI Opportunity Fund,“ said Tom Serena, CEO of the American Gastroenterological Association.
Accelerating Commercial Growth
Luminoah will use the new Series B capital to:
- Expand distribution: Bring Luminoah Flow to more home medical equipment (HME) suppliers and health systems across the U.S.
- Scale manufacturing: Expand production capacity and introduce automation for the Luminoah Flow system.
- Advance Luminoah Intelligence: Continue development of a clinician-facing data platform.
“Early access showed us how Luminoah Flow fits into a patient’s daily routine. Reaching thousands of patients takes distribution partners, manufacturing at scale, and software clinicians will actually use. Our Series B financing enables us to focus on these key initiatives,” said Garrett Marin, Chief Operating Officer of Luminoah.
Read more here.